# US 8,541,589 B2 · Thioacetate compounds, compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,589 B2
- Document ID: US8541589B2
- Status: Granted
- Kind: B2
- Application number: 13/857,108
- Filed: 2013-04-04
- Published: 2013-08-08
- Granted: 2013-09-24
- Earliest claimed: 2010-06-16
- Assignees: Ardea Biosciences, Inc.
- Applicants: Ardea Biosciences, Inc.
- Inventors: Samedy Ouk; Esmir Gunic; Jean-Michel Vernier
- Web page: https://patentgrep.com/patent/US8541589B2

## CPC

- C07D 213/70: Sulfur atoms
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/497: containing further heterocyclic rings
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- C07D 239/38: One sulfur atom
- C07D 241/18: Oxygen or sulfur atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

## Claims

### Claim 1

A compound of formula:
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2

A pharmaceutical composition comprising a compound of formula:
or a pharmaceutically acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, together with a xanthine oxidase inhibitor.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the xanthine oxidase inhibitor is allopurinol.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the xanthine oxidase inhibitor is febuxostat.

### Claim 6

A compound having the structure:

### Claim 7

A pharmaceutical composition comprising a compound having the structure:
and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, together with a xanthine oxidase inhibitor and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the xanthine oxidase inhibitor is allopurinol.

### Claim 10 (depends on 8)

The pharmaceutical composition of claim 8, wherein the xanthine oxidase inhibitor is febuxostat.